Rxwire
In the news · 48h FDA 34 Eli Lilly 15 Roche 10 Johnson & Johnson 8 AbbVie 3 AstraZeneca 3 Merck & Co. (MSD) 3 Pfizer 2
Approvals & regulatory · first seen 49m ago, updated 49m ago

FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata

1 outlet Eli Lilly FDA

FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant resulted in substantial scalp hair regrowth…

Summary from PR Newswire - Clinical Trials.

Coverage 1 article · 1 outlet

  1. PR Newswire - Clinical Trials
    FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata